Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

ImmunityBio (IBRX) Long-Term Debt Repayments (2016 - 2018)

ImmunityBio (IBRX) has disclosed Long-Term Debt Repayments for 5 consecutive years, with $142000.0 as the latest value for Q4 2018.

  • Quarterly Long-Term Debt Repayments rose 121.88% to $142000.0 in Q4 2018 from the year-ago period, while the trailing twelve-month figure was $477000.0 through Dec 2018, down 97.61% year-over-year, with the annual reading at $1.1 million for FY2025, N/A changed from the prior year.
  • Long-Term Debt Repayments for Q4 2018 was $142000.0 at ImmunityBio, up from $137000.0 in the prior quarter.
  • The five-year high for Long-Term Debt Repayments was $14.9 million in Q3 2017, with the low at $1000.0 in Q4 2014.
  • Average Long-Term Debt Repayments over 5 years is $1.5 million, with a median of $64500.0 recorded in 2017.
  • The sharpest move saw Long-Term Debt Repayments skyrocketed 149380.0% in 2017, then plummeted 99.08% in 2018.
  • Over 5 years, Long-Term Debt Repayments stood at $1000.0 in 2014, then soared by 100.0% to $2000.0 in 2015, then surged by 1000.0% to $22000.0 in 2016, then soared by 190.91% to $64000.0 in 2017, then soared by 121.88% to $142000.0 in 2018.
  • According to Business Quant data, Long-Term Debt Repayments over the past three periods came in at $142000.0, $137000.0, and $133000.0 for Q4 2018, Q3 2018, and Q2 2018 respectively.